Evidence Trace, complete trial record
In plain terms
In plain terms: Collagen Peptides has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.
Collagen Peptides
B
Supported: a good trial, backed by more
The endpoint this grade is based on: self_report, Graded by use. Activity-related joint pain in athletes and active adults: Grade B, three randomized trials agree on self-reported pain, the ceiling for self-report. Skin hydration, elasticity and wrinkles: Grade C, pooled analyses are positive overall and null in the independent and high-quality trials. None of the graded trials measured bone density; a 12-month trial in postmenopausal women is noted but not graded.
The evidence as the record states it
Joint pain: Clark et al. (Curr Med Res Opin, 2008; PMID 18416885): 147 varsity and club athletes with activity-related joint pain, 10 g/day collagen hydrolysate for 24 weeks, data evaluable in 97; five self-rated pain parameters and one physician-rated parameter improved against placebo. Funding is not stated in its indexed record. Zdzieblik et al. (Appl Physiol Nutr Metab, 2017; PMID 28177710): 139 athletes with functional knee pain, 5 g/day specific collagen peptides for 12 weeks; activity-related pain on a visual analogue scale, the primary outcome, improved against placebo (p = 0.046), resting pain did not; one of its authors is at the Collagen Research Institute, Kiel, an industry research body. Kviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682): 9-month double-blind trial in middle-aged active adults, placebo versus 10 or 20 g/day; KOOS pain and activities-of-daily-living scores improved at 10 g/day over 6 months, the pain effect only in those exercising more than 180 minutes a week; the paper lists an NIH training grant and reports no conflicts. Skin: Myung and Park (Am J Med, 2025; PMID 40324552): meta-analysis of 23 randomized trials, 1,474 participants, positive overall for hydration, elasticity and wrinkles, but null in trials without company funding and null in high-quality trials, so the positive skin results are concentrated in company-funded trials. Pu et al. (Nutrients, 2023; PMID 37432180): meta-analysis of 26 randomized trials, 1,721 participants, hydration and elasticity improved, with several biases noted and no difference in elasticity by collagen source. Choi et al. (J Drugs Dermatol, 2019; PMID 30681787): qualitative systematic review of 11 trials, not a meta-analysis; context. Mechanistic context, not graded: Shaw et al. (Am J Clin Nutr, 2017; PMID 27852613): 8 men, 3 days, crossover of vitamin C-enriched gelatin, measuring a blood collagen-synthesis marker and engineered ligaments in the laboratory; funded by the National Institute on Aging; a different preparation and a surrogate marker. Bone, not graded here: König et al. (Nutrients, 2018; PMID 29337906): 131 postmenopausal women, 5 g/day specific collagen peptides for 12 months, spine and femoral neck bone density higher than placebo; one author is at the Collagen Research Institute.
PMID 18416885 PMID 28177710 PMID 37551682 PMID 40324552 PMID 37432180 PMID 30681787 PMID 27852613 PMID 29337906
Evidence by specific use
Activity-related joint pain in athletes and active adults
Grade B
Three randomized placebo-controlled trials agree. Clark et al. (Curr Med Res Opin, 2008; PMID 18416885): 147 athletes with activity-related joint pain, 10 g/day for 24 weeks, 97 evaluable; five self-rated pain parameters and one physician-rated parameter improved against placebo; funding not stated. Zdzieblik et al. (Appl Physiol Nutr Metab, 2017; PMID 28177710): 139 athletes with functional knee pain, 5 g/day for 12 weeks; activity-related pain, the primary outcome, improved against placebo (p = 0.046); one author at an industry collagen research institute. Kviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682): middle-aged active adults, 10 or 20 g/day for 9 months; KOOS pain and daily-living scores improved at 10 g/day over 6 months, the pain effect only in those exercising more than 180 minutes a week; NIH training grant, no conflicts reported. Replicated randomized evidence on self-reported pain: B, the ceiling for self-report. The three trials span unstated, industry-affiliated and independent funding, so no single funder stands behind the letter.
PMID 18416885 PMID 28177710 PMID 37551682
Skin hydration, elasticity and wrinkles in adults
Grade C
Myung and Park (Am J Med, 2025; PMID 40324552): meta-analysis of 23 randomized trials, 1,474 participants; positive overall for hydration, elasticity and wrinkles, but null in trials without company funding and null in high-quality trials, so the positive results are concentrated in company-funded trials. Pu et al. (Nutrients, 2023; PMID 37432180): 26 trials, 1,721 participants, hydration and elasticity improved with several biases noted. A pooled result that disappears in the independent and the high-quality trials is mixed evidence: C.
PMID 40324552 PMID 37432180
Why Grade B and not Grade A
Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, Collagen Peptides would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.
What this grade covers and what it does not
Grade B, the record's best use: activity-related joint pain in athletes and active adults, where three randomized placebo-controlled trials agree. Clark et al. (Curr Med Res Opin, 2008; PMID 18416885; 147 athletes, 24 weeks), Zdzieblik et al. (Appl Physiol Nutr Metab, 2017; PMID 28177710; 139 athletes, 12 weeks) and Kviatkovsky et al. (J Int Soc Sports Nutr, 2023; PMID 37551682; middle-aged active adults, 9 months) each found self-reported activity-related pain lower than placebo. Replicated randomized evidence on a self-reported endpoint is B, and self-report is what keeps it from A. The three trials span unstated, industry-affiliated and independent funding, so no single funder stands behind the letter. SKIN CARRIES ITS OWN C: Myung and Park (Am J Med, 2025; PMID 40324552) found the pooled benefit on hydration, elasticity and wrinkles disappears in trials without company funding and in high-quality trials, and Pu et al. (Nutrients, 2023; PMID 37432180) note several biases; a pooled result that depends on funded trials is mixed. The bundled headline was moved B to C in October 2026 because the uses were mixed together; split in October 2026 by the written rule, each use carries its own letter and the headline follows the best. WHAT THIS GRADE DOES NOT COVER: bone density, where one 12-month trial in postmenopausal women (König et al., 2018; PMID 29337906) is noted but not graded; gelatin with vitamin C as a separate preparation (Shaw et al., 2017; PMID 27852613); knee osteoarthritis, a clinical population the joint trials did not enroll; and people who do not exercise, in whom the largest trial found no pain effect.
What would move this grade
An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.
How to track whether this is working
Joint pain scores, skin elasticity (clinical photography), bone density (DEXA) if primary indication